What Mobility Health does

Mobility Health, doing business as Mira Precision Health, is a CLIA-certified clinical laboratory founded in 2021 and headquartered in Mason, Ohio. The company operates a pharmacogenomic (PGx) testing platform built around two branded products: Mira Comprehensive PGx, a broad panel covering 85+ commonly prescribed medications across 12 therapeutic areas (mental health, cardiology, pain management, oncology, autoimmune disorders, organ transplants, infection/immunity), and ToxNav Advantage, an oncology-focused test covering all AMP Tier 1 and Tier 2 DPYD variants plus UGT1A1 testing for irinotecan dosing, with results aligned to FDA labeling and NCCN Clinical Practice Guidelines. Testing is supported by a clinical decision support software layer, a proprietary laboratory platform designed to handle low-quality DNA samples, and a web-based provider portal for ordering and results retrieval. Scientific underpinning for the oncology franchise is provided through a partnership with Oxford Cancer Biomarkers.

The company sells primarily to community clinics, healthcare providers, and long-term care facilities through a direct sales motion, with testing delivered via the provider portal and reimbursed under Medicare. All services feature a stated 48-hour turnaround time. Beyond PGx, the lab also offers in-vitro diagnostics, custom molecular assay development and validation for clinical and research partners, and serological testing for infectious disease detection. The company maintains CLIA certification (CLIA# 36D2194362), HITRUST certification, HIPAA/HITECH compliance, GINA adherence, and WBENC women-owned business certification. There are no disclosed funding rounds, ownership details, revenue figures, or named enterprise customers in the available data.

Name

Mobility Health

Legal name

Mira Precision Health

Website

https://mobilityhealthlab.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Mobility Health (Mira Precision Health) is a CLIA-certified clinical laboratory offering pharmacogenomic testing across 85+ medications and 12 therapeutic areas for community clinics, healthcare providers, and long-term care facilities, with 48-hour turnaround and Medicare reimbursement.

Ownership category

akta.pro rank

Product category

Pharmacogenomic Testing Services

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

Keywords

• Pharmacogenomic testing
• Precision medicine diagnostics
• Clinical laboratory services
• Oncology genetic testing
• DNA-guided prescribing

Headquarters

HQ city

Mason

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Medicare-Covered PGx Testing: Laboratory testing services for pharmacogenomic testing that is covered by Medicare, indicating reimbursement through government healthcare programs. The company provides testing services to healthcare providers who order tests for their patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Mobility Health (operating as Mira Precision Health) is a CLIA-certified clinical laboratory providing pharmacogenomic (PGx) testing services to healthcare providers. Its two flagship offerings are Mira Comprehensive PGx, covering 85+ medications across 12 therapeutic areas, and ToxNav Advantage, an oncology-focused test covering all AMP Tier 1 and Tier 2 DPYD variants plus UGT1A1 testing to assess chemotherapy toxicity risk. Tests are delivered with an industry-best 48-hour turnaround time through a secure provider portal with EMR integration.

Product overview

Mira Precision Health (Mobility Health) offers a pharmacogenomic testing platform consisting of two main branded test products: Mira Comprehensive PGx for general medication guidance across 85+ medications in 12 therapeutic areas, and ToxNav Advantage for specialized oncology pharmacogenomic testing to reduce chemotherapy toxicity. These products are supported by proprietary clinical decision support software, delivered through a provider portal, and backed by CLIA-certified in-vitro diagnostic laboratory services. All products feature a 48-hour turnaround time.

Differentiator

Problem solved

Functional benefit

Brands

• ToxNav Advantage: Oncology pharmacogenomic testing for DPYD and UGT1A1 variants to help reduce chemotoxicity from fluoropyrimidines and irinotecan.
• Mira Comprehensive PGx

Products and services

• Mira Comprehensive PGx Comprehensive pharmacogenomic test providing medication guidance for 85+ commonly prescribed medications across 12 therapeutic areas including mental health, cardiology, pain management, infection/immunity, oncology, autoimmune disorders, and organ transplant care. Delivered with a 48-hour turnaround time to healthcare providers for use in clinical decision-making.
• ToxNav Advantage Oncology-focused pharmacogenomic test covering all AMP Tier 1 and Tier 2 DPYD variants for fluoropyrimidine toxicity risk plus UGT1A1 testing for irinotecan dosing guidance. Results are aligned with FDA labeling and NCCN Clinical Practice Guidelines in Oncology. Powered by Oxford Cancer Biomarkers science, with a 48-hour turnaround time.
• In-Vitro Diagnostics Laboratory Services CLIA-certified high-complexity clinical laboratory services specializing in advanced nucleic acid analysis, assay development and validation, and high-throughput molecular testing. Offered to laboratories, pharmaceutical partners, and clinical or R&D teams seeking custom diagnostic programs and precision-medicine initiatives.
• Serological Testing In-vitro diagnostic services for infectious disease detection and immunity assessment, provided through the company's CLIA-certified laboratory. Targeted at healthcare providers needing serological testing support.

Quantifiable outcome

• Industry-best 48-hour turnaround time for pharmacogenomic test results
• +3 more outcomes

Named customers3 records

Segments3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Oxford Cancer BiomarkerscoreTechnology or IntegrationOxford Cancer Biomarkers provides the scientific foundation powering Mira Precision Health's ToxNav Advantage oncology testing platform. The partnership enables DPYD and UGT1A1 testing with results aligned to FDA labeling and NCCN Guidelines.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Tempus Labs: Tempus is a large precision medicine platform combining molecular profiling, data, and AI. It is a broad incumbent covering oncology molecular diagnostics and PGx-adjacent testing, competing for the same provider and oncology accounts.
• Caris Life Sciences: Caris provides molecular profiling and AI-driven precision medicine, notably in oncology. It is a broad incumbent that overlaps with Mira's oncology pharmacogenomic and molecular diagnostic ambitions at a much larger scale.
• GeneDx: GeneDx is an established clinical genetics and rare disease diagnostics company with broad hereditary and pharmacogenomic offerings. As a broad incumbent with national infrastructure, it competes for similar provider accounts in clinical genetic testing.
• Castle Biosciences: Castle Biosciences is a molecular diagnostics company specializing in dermatologic and oncology tests. It is a broad incumbent in specialty molecular diagnostics, relevant as a competitor for provider-directed, oncology-related testing.
• Myriad Genetics (Assurex Health): Myriad Genetics acquired Assurex Health to offer GeneSight, a leading mental-health PGx test. As a large, publicly traded genetics company, it is a broad incumbent that overlaps with Mira's PGx offerings but operates across a much wider diagnostic portfolio.
• PathGroup: PathGroup is a large reference laboratory offering molecular and clinical testing across the Southeast and broader US. It is a broad incumbent in clinical laboratory services with overlapping capabilities to Mira's CLIA-certified diagnostic offerings.

Direct peers

• OneOme: OneOme is a pharmacogenomic decision support platform offering RightMed, a multi-gene PGx test used by providers for medication guidance across similar therapeutic areas. It directly competes with Mira Comprehensive PGx in clinical pharmacology testing for healthcare providers.
• Genomind: Genomind is a PGx testing company focused on mental health medication management, with its Genecept Assay covering psychotropic-relevant genes. It is a direct competitor in the provider-ordered PGx testing category, particularly overlapping with Mira's mental health therapeutic area.
• RxGenomix: RxGenomix provides PGx interpretation and clinical decision support for pharmacists and providers. It directly competes in the same medication-management-PGx category as Mira Precision Health.
• Coriell Life Sciences: Coriell Life Sciences offers pharmacogenomic testing and clinical interpretation services for healthcare organizations. It is a direct peer in PGx decision support with a similarly provider-focused go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/100083523728182
• LinkedInlinkedin.com/company/mobility-health-lab

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mobility Health